Letvex

Letvex

letrozole

Manufacturer:

Vexxa Lifesciences

Distributor:

Ashro

Marketer:

Ashro
Concise Prescribing Info
Contents
Letrozole
Indications/Uses
Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following antiestrogen therapy.
Dosage/Direction for Use
Adult & elderly 2.5 mg once daily. Duration of treatment: Adjuvant therapy: Continue for 5 years or until tumour relapse occurs, which ever comes first. Metastatic disease: Continue until tumor progression is evident.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pre-op use if receptor status is -ve or unknown. Severe hepatic impairment (Child-Pugh grade C). Premenopausal, pregnant or lactating women.
Special Precautions
Breast cancer in men. Reductions in bone mineral density may occur. Assess bone mineral density eg, DEXA scanning at the start of treatment in women w/, or at risk of osteoporosis; initiate treatment of osteoporosis & carefully monitor patients. Patients w/ CrCl <10 mL/min. Not recommended in childn.
Adverse Reactions
Hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, increased sweating, bone pain; & musculoskeletal effects.
Drug Interactions
Reduced plasma levels w/ coadministration of tamoxifen.
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Letvex FC tab 2.5 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in